Evidence map›Paper›PMID 29499727›Full record

ArticleJournal of translational medicine2018

Distinct alterations of CD68

Xia Shao, Boting Wu, Luya Cheng, Feng Li, Yanxia Zhan, Chanjuan Liu, Lili Ji, Zhihui Min, Yang Ke, Lihua Sun and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Xia ShaoDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, 200032, China.
Boting WuDepartment of Transfusion Medicine, Zhongshan Hospital Fudan University, Shanghai, 200032, China.
Luya ChengDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, 200032, China.
Feng LiDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, 200032, China.
Yanxia ZhanDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, 200032, China.
Chanjuan LiuDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, 200032, China.
Lili JiDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, 200032, China.
Zhihui MinInstitute of Clinical Science, Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Rd, Shanghai, 200032, China.
Yang KeDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, 200032, China.
Lihua SunDepartment of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, 201700, China.
Hao ChenDepartment of Thoracic Surgery, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, 201700, China.
Yunfeng ChengDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, 200032, China. yfcheng@fudan.edu.cn.
Fudan University · CNSun Yat-sen University · CNShanghai Center For Bioinformation Technology · CNThe First Affiliated Hospital, Sun Yat-sen University · CNZhongshan Hospital · CN

Funding

National Natural Science Foundation of China 81170473National Natural Science Foundation of China 81300381National Natural Science Foundation of China 81470282National Natural Science Foundation of China 81500090National Natural Science Foundation of China 81600090
6 · The paper itself

Abstract

backgroundAlthough impaired myeloid-derived suppressor cells (MDSCs) recently have been studied in immune thrombocytopenia (ITP), another myeloid-derived cell population signified as M2 macrophages has not been investigated properly in ITP patients. In the present study, we intended to determine the features of circulating M2-like macrophages, to examine its relationship with MDSCs, and to explore their prognostic values in ITP.

methodsPeripheral blood mononuclear cells from healthy controls and primary ITP patients were isolated to test the circulating M2-like macrophages and MDSCs. The circulating M2-like macrophage population defined as CD68

resultsThe percentages of MDSCs were found to be expanded in newly diagnosed patients of ITP, especially among those of the complete response (CR) group (p < 0.0001). Positive linear correlation was verified between percentages of M2-like macrophages and MDSCs. The same correlation was also determined in the CR group. After treatment, the percentages of M2-like macrophages and MDSCs were both increased significantly in CR group, while those patients among the PR + NR group manifested a significant numeric decrease of MDSCs but only a moderate decrease in M2-like macrophages. MIP-1α/CCL3 was negatively correlated with M2-like macrophages while MCP-1 possessed a positive correlation with M2-like macrophages, eotaxin-1/CCL11 was negatively correlated with MDSCs and interleukin-1β (IL-1β) was found to be negatively correlated with both M2-like macrophages and MDSCs.

conclusionsThe present findings indicated critical roles of both circulating M2-like macrophages and MDSCs in ITP. The positive correlation between them might be related to inflammatory factors-mediated bidirectional interactions or partially due to their similar background patterns during differentiation. MIP-1α/CCL3, MCP-1, eotaxin-1/CCL11 and IL-1β might play a critical role in the expansion of both M2 macrophages and MDSCs population in ITP patients, which deserves further investigation.

Indexed as

AdultAgedAged, 80 and overAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenCD68 MoleculeCell ProliferationCytokinesDexamethasoneFemaleHumansMacrophagesMaleMiddle AgedMyeloid-Derived Suppressor CellsAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenCD68 antigen, humanCD68 MoleculeCytokinesDexamethasoneReceptors, Cell SurfaceDexamethasoneImmune thrombocytopeniaM2-like macrophagesMDSCs

Identifiers

PMID29499727
PMCPMC5833082
OpenAlexW2797517257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.